Article summary
AtaiBeckley is in structured discussions with pharma companies and royalty investors about a potential partnership for its lead candidate, intranasal 5-MeO-DMT (BPL-003) for treatment-resistant depression (TRD), sources close to the company told Psychedelic Alpha. Here, we take a closer look...
Continue to the original publication for the complete article.